Efficacy of liraglutide in the treatment of type 2 diabetes mellitus complicated by osteoporosis and its effects on serum chemokines and bone mineral density
10.3760/cma.j.cn341190-20221030-00863
- VernacularTitle:利拉鲁肽治疗T2DM合并骨质疏松效果观察及对血清趋化素和骨密度的影响
- Author:
Binli ZHONG
1
;
Yan ZHANG
Author Information
1. 厦门大学附属第一医院思明院区内科，厦门 361000
- Keywords:
Diabetes mellitus,type 2;
Osteoporosis;
Liraglutide;
Chemokines;
Chemerin;
Bone density;
Blood glucose;
Hemoglobin A,glycosylated
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(11):1605-1609
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of liraglutide in the treatment of type 2 diabetes mellitus complicated by osteoporosis and its effects on serum chemokines and bone mineral density.Methods:This is a case-control study. The clinical data of 78 patients with type 2 diabetes mellitus complicated by osteoporosis who received treatment in the Siming Branch of The First Affiliated Hospital of Xiamen University from May 2019 to September 2021 were retrospectively analyzed. These patients were divided into an observation group and a control group ( n = 39 per group) according to different treatment methods. The control group was treated with adjuvant therapy with afacalcitol, while the observation group was given liraglutide in addition to adjuvant therapy with afacalcitol. Both groups were treated for 16 weeks. Clinical efficacy was compared between the two groups. Before and after treatment, serum chemokines and bone mineral density were determined in each group. Adverse reactions were evaluated in each group. Results:The total effective rate in the observation group was 92.3% (36/39), which was significantly higher than 71.8% (28/39) in the control group ( χ2 = 5.57, P < 0.05). After treatment, the serum chemokine level in the observation group was (60.11±10.25) μg/L, which was significantly lower than (63.15 ± 10.24) μg/L in the control group ( t = -2.01, P < 0.05). Bone mineral density in the observation group was (1.77 ± 1.05) g/cm 2, which was significantly higher than (1.01 ± 0.06) g/cm 2 in the control group ( t = 4.51, P < 0.05). The incidence of adverse reactions in the observation group was 7.7% (3/39), which was not significantly different from 12.8% (5/39) in the control group ( χ2 = 0.56, P > 0.05). Conclusion:Liraglutide is highly effective on type 2 diabetes mellitus complicated by osteoporosis. Liraglutide can effectively decrease serum chemokine levels, increase bone mineral density, and thereby is worthy of clinical application.
